Using hydrogel microparticles to improve CAR-T cell therapies for cancer treatment
Official title: Hydrogel microparticle technology for high-throughout screening of chimeric antigen receptor-T cells based on single cell effector function
Funded at Partillion Bioscience Corporation · NIH-10922670 · Data updated 2026-11-12
This study is working on improving CAR-T cell therapies for cancer by using special technology to find the best CAR-T cells that can fight tumors, which could lead to better treatments for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Partillion Bioscience Corporation NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 6, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $741,926 |
| NIH project number | 5R44GM149102-02 |
| Project ID | NIH-10922670 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors who may benefit from advanced CAR-T cell therapies.
✕Less likely to help
Patients with hematologic malignancies may not benefit directly from this research, as it focuses on solid tumors.
What this research studies
This research focuses on enhancing chimeric antigen receptor (CAR)-T cell therapies, which are designed to treat various cancers, including solid tumors. By utilizing hydrogel microparticle technology, the project aims to develop high-throughput screening methods that can analyze individual CAR-T cells based on their functional capabilities. This approach will allow researchers to identify and select the most effective CAR-T cells from a large population, potentially leading to more successful treatments. The study also seeks to connect functional data with genetic information to better understand how to improve CAR-T cell performance in challenging tumor environments.
Why it matters
Potential benefit: If successful, this research could lead to more effective CAR-T cell therapies, improving treatment outcomes for patients with solid tumors.
How similar studies have gone: Other research has shown promise in enhancing CAR-T cell therapies, but this specific approach using hydrogel microparticles is relatively novel.
Where this research is happening
-
Partillion Bioscience Corporation
Los Angeles, United States Active
Researchers
- Principal investigator: De Rutte, Joseph — Partillion Bioscience Corporation
- Study coordinator: De Rutte, Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.